Related Experiment Video

Updated: Apr 6, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma

Ali Rihani1, Jo Vandesompele1, Frank Speleman1

  • 1Center for Medical Genetics, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.

Cancer Cell International
|July 31, 2015
PubMed
Abstract

Insights

Targeting cell cycle genes like CCND1 and PLK1, and inhibiting cyclin-dependent kinases 4/6 (CDK4/6) with palbociclib, shows promise for treating neuroblastoma, a common childhood cancer.

Area of Science:

  • Oncology
  • Cell Biology
  • Pediatric Cancer Research

Background:

  • Neuroblastoma is a prevalent cancer in infants, originating from neural crest cells.
  • Cell cycle gene aberrations are implicated in neuroblastoma development and represent potential therapeutic targets.

Purpose of the Study:

  • To investigate the role of cell cycle regulatory genes in neuroblastoma pathogenesis.
  • To identify novel therapeutic targets for neuroblastoma treatment.

Main Methods:

  • Screening of 131 cell cycle genes using siRNA-mediated gene silencing.
  • Assessing the impact of gene silencing on neuroblastoma cell proliferation.
  • Pharmacological inhibition of cyclin-dependent kinases 4/6 (CDK4/6) using palbociclib.

Main Results:

  • Knockdown of CCND1 and PLK1 significantly reduced neuroblastoma cell proliferation.
  • Palbociclib treatment inhibited neuroblastoma cell line growth and induced G1 cell cycle arrest.
  • The cyclin D1-Rb pathway was inhibited by palbociclib.

Conclusions:

  • Selective CDK4/6 inhibition with palbociclib demonstrates potential as a therapeutic strategy for neuroblastoma.
  • Targeting the cell cycle offers a promising avenue for novel neuroblastoma treatments.
Keywords:
Cell cycleCyclin D1NeuroblastomaPalbociclibTargeted therapy

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
764
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K